Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Corcept Therapeutics Incorporated (CORT)

December 27, 2019 GMT

SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)--Dec 26, 2019--

Shareholder rights law firm Robbins LLP announces that a purchaser of Corcept Therapeutics Incorporated (NASDAQ: CORT) filed a complaint against the company’s officers and directors for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept’s drug Korylm is a cortisol receptor blocker used to control hyperglycemia.

If you have suffered a loss as a result of Corcept’s misconduct, click here.

Corcept Therapeutics Incorporated (CORT) Accused of Illicit Sales Practices

According to the complaint, in 2012, Corcept launched its prescription medicine Korlym, which served as Corcept’s only revenue-generating product. Due to the limited population of potential Korlym users, Corcept’s officers and directors improperly paid doctors to prescribe Korlym for non-approved applications and disguised these bribes as speaking fees for its speakers bureau program. Then, on January 25, 2019, Corcept’s ruse was revealed when Southern Investigative Reporting Foundation published a report alleging that Corcept paid doctors to prescribe Korlym for off-label uses. In addition to this wrongdoing, on February 5, 2019, Blue Orca Capital published a report alleging that the specialty pharmacy Corcept switched to for processing Korlym orders was actually an undisclosed related party that Corcept was using to artificially boost sales and hide losses. As a result of these revelations, Corcept’s public statements appeared to be materially false and misleading, damaging the Company’s credibility. As a result, Corcept has been named a defendant in a securities class action lawsuit, opening the Company up to future damages.

Corcept Therapeutics Incorporated (CORT) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191226005103/en/

CONTACT: Leo Kandinov

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122


(619) 525-3990 or Toll Free (800) 350-6003





Copyright Business Wire 2019.

PUB: 12/26/2019 07:25 PM/DISC: 12/26/2019 07:25 PM